Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-14
2009-08-25
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C424S134100, C530S350000, C530S387300
Reexamination Certificate
active
07579316
ABSTRACT:
Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the administration of a potentially immunogenic substance. Another method contemplates tolerizing a subject to a therapeutic molecule that is or is capable of being immunogenic by the administration of CTLA-4. Various embodiments of CTLA-4 are also disclosed.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4289872 (1981-09-01), Denkewalter et al.
patent: 4710473 (1987-12-01), Morris
patent: 5229490 (1993-07-01), Tam
patent: 6251957 (2001-06-01), Wilson et al.
patent: 6372208 (2002-04-01), Wilson et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 2003/0211078 (2003-11-01), Heavner
patent: 036676 (1981-09-01), None
patent: 058481 (1982-08-01), None
patent: 088046 (1983-09-01), None
patent: 133988 (1985-03-01), None
patent: 143949 (1985-06-01), None
patent: 0422339 (1991-04-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 93/21259 (1993-10-01), None
patent: WO 95/34326 (1995-12-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/33513 (1998-08-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 01/92337 (2001-12-01), None
patent: WO 02/02638 (2002-01-01), None
Levi-Montalcini et al., J. Neurol. Sci., 1995, 130: 119-127.
Cohen et al., 1986, Press Release of the Nobel Assembly at the Karolinska Institute, 5 pages.
Chamberlain, P. et al. “An Overview of Scientific and Regulatory Issues for the Immunogenicity of Biological Products.”Immunogenicity of Therapeutic Biological Products, Dev. Biol. Basel, Karger112:3-11 (2003).
Chang, C-C.J. et al. “Evolution of a Cytokine Using DNA Family Shuffling.”Nature Biotechnology17:793-797 (1999).
Davis, C.G. et al. “Transgenic Mice as a Source of Fully Human Antibodies for the Treatment of Cancer.”Cancer and Metastasis Reviews18:421-425 (1999).
Ellison, J.W. et al. “The Nucleotide Sequence of a Human Immunoglobulin Cγ1Gene.”Nucleic Acids Res.10: 4071-79 (1982).
Eppstein, D.A. et al. “Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by a Cell Membrane Receptor.”Proc. Natl. Acad. Sci. USA82:3688-3692 (1985).
Green, L.L. “Antibody Engineering Via Genetic Engineering of the Mouse: ZenoMouse Strains are a Vehicle for the Facile Generation of Therapeutic Human Monoclonal Antibodies.”J. Immunol. Meth.231:11-23 (1999).
Herzyk, D.J. “The Immunogenicity of Therapeutic Cytokines.”Current Opinion in Molecular Therapeutics5(2):167-171 (2003).
Isaacs, J.D. “The Antiglobulin Response to Therapeutic Antibodies.”Seminars in Immunology2(6):449-456 (1990).
Issacs, J.D. “From Bench to Bedside: Discovering Rules for Antibody Design, and Improving Serotherapy with Monoclonal Antibodies.”Rheumatology40:724-738 (2001).
Koren, E. et al. “Immune Responses to Therapeutic Proteins in Humans—Clinical Significance, Assessment and Prediction.”Current Pharmaceutical Biotechnology3(4):349-360 (2002).
Kurtzman, A.L. et al. “Advances in Directed Protein Evolution by Recursive Genetic Recombination: Applications to Therapeutic Proteins.”Current Opinion in Biotechnology12:361-370 (2001).
Langer, R. et al. “Biocompatibility of Polymeric Delivery Systems for Macromolecules.”J. Biomed. Mater. Res.15:267-277 (1981).
Langer, R. “Controlled Release of Macromolecules.”Chemtech12:98-105 (1982).
Porter, S. “Human Immune Response to Recombinant Human Proteins.”J. Pharmaceutical Sciences90(1):1-11 (2001).
Rosenberg, J.J. et al. “Development of a Novel, Nonimmunogenic, Soluble Human TNF Receptor Type I (sTNFR-I) Construct in the Baboon.”J. Appl. Physiol.91:2213-2223 (2001).
Rosenberg, A.S. “Immunogenicity of Biological Therapeutics: A Hierarchy of Concerns.”Immunogenicity of Therapeutic Biological Products, Dev. Biol. Basel, Karger112:15-21 (2003).
Schellekens, H. et al. “Immunogenicity of Biopharmaceuticals. The European Perspective.”Immunogenicity of Therapeutic Biological Products, Dev. Biol. Basel, Karger, 112:23-38 (2003).
Schroff, R.W. et al. “Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy.”Cancer Res.45(2):879-885 (1985).
Sidman, K.R. et al. “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid.”Biopolymers22:547-556 (1983).
Stein, K.E. “Immunogenicity: Concepts/Issues/Concerns.”Biologics 2000—Comparability of Biotechnology Products Dev. Bio. Basel, Karger109:15-23 (2002).
Tsutsumi, Y. et al. “Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity.”Proc. Natl. Acad. Sci.97:8548-8553 (2000).
Feige Ulrich
Khare Sanjay D.
Amgen Inc.
Ouspenski Ilia
Perkins Coie LLP
LandOfFree
Compositions and methods to modulate an immune response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods to modulate an immune response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods to modulate an immune response to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120272